Cytocom, Inc. (CBLI)

Cytocom, Inc. (CBLI) Healthcare & Pipeline Overview

Cytocom, Inc., a biopharmaceutical firm based in Buffalo, NY, specializes in immune system activation through Toll-like receptor technology. Their lead candidate, Entolimod, targets radiation injury and oncology, positioning them in the immunotherapy sector with potential applications across multiple serious medical conditions. The company also develops CBLB612, Mobilan and CBL0137.

What Is the Investment Thesis for CBLI?

Cytocom, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on Toll-like receptor activators for radiation countermeasures and immuno-oncology provides exposure to niche markets with significant growth potential. The primary value driver is the successful development and regulatory approval of Entolimod, their lead product candidate. Positive clinical trial results and subsequent FDA approval for either radiation mitigation or oncology indications could trigger a substantial increase in the company's market capitalization. However, the company's negative profit margin of -912.2% highlights the significant financial risks associated with drug development. Investors should closely monitor clinical trial outcomes, regulatory milestones, and the company's ability to secure additional funding to sustain operations through 2026 and beyond.

Based on FMP financials and quantitative analysis

CBLI Key Highlights

• Market capitalization of $0.23 billion reflects investor valuation of Cytocom's pipeline and technology platform as of March 15, 2026.
• Negative P/E ratio of -16.38 indicates that Cytocom is currently not profitable, typical for biotechnology companies in the development stage.
• Gross margin of 100.0% suggests high potential profitability for approved products, but this is contingent on successful commercialization.
• Profit margin of -912.2% highlights the significant expenses associated with research and development in the biopharmaceutical industry.
• Beta of 0.68 indicates lower volatility compared to the overall market, which may appeal to risk-averse investors.

Who Are CBLI's Competitors?

What Are CBLI's Key Strengths?

• Proprietary Toll-like receptor technology.
• Lead product candidate (Entolimod) in advanced development.
• Potential for both radiation countermeasure and oncology applications.
• Experienced management team.

What Are CBLI's Weaknesses?

• Significant financial losses and negative profit margin.
• Dependence on successful clinical trial outcomes.
• High regulatory hurdles and approval risks.
• Limited commercialization experience.

What Could Drive CBLI Stock Higher?

• Clinical trial results for Entolimod in radiation mitigation.
• Clinical trial results for Entolimod in oncology indications.
• Potential government contracts for radiation countermeasures.
• Advancements in Toll-like receptor technology platform.
• Strategic partnerships with pharmaceutical companies.

What Are the Key Risks for CBLI?

• Clinical trial failures for Entolimod.
• Regulatory setbacks and delays.
• Competition from established pharmaceutical companies.
• Inability to secure additional funding.
• Intellectual property challenges.

What Are the Growth Opportunities for CBLI?

• Entolimod for Radiation Countermeasure: Cytocom is developing Entolimod as a radiation countermeasure, targeting a market driven by government stockpiling and biodefense initiatives. The market size is projected to reach billions of dollars, driven by increasing global security concerns. Securing a government contract for Entolimod could provide a significant revenue stream and validate the company's technology. Timeline for potential approval and commercialization is estimated within the next 3-5 years, pending successful clinical trials.
• Entolimod for Oncology: Entolimod is also being investigated as an immunotherapy for various oncology indications. The immuno-oncology market is experiencing rapid growth, with a global market size projected to reach hundreds of billions of dollars by 2030. Positive clinical trial results in specific cancer types could lead to accelerated approval pathways and significant market penetration. Competition in this space is intense, requiring Cytocom to demonstrate superior efficacy and safety profiles.
• CBLB612 Development: CBLB612, a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor, represents a potential growth opportunity for Cytocom. Further development and clinical trials could unlock its therapeutic potential in various inflammatory and autoimmune diseases. The market for TLR2/TLR6 agonists is growing, driven by increasing understanding of the role of innate immunity in disease pathogenesis. The timeline for commercialization depends on successful preclinical and clinical studies.
• Mobilan for Immunotherapy: Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. It represents another growth opportunity for Cytocom in the immunotherapy space. Development of Mobilan as a novel cancer therapy could attract partnerships and funding. The market for adenoviral-based therapies is expanding, driven by advancements in gene therapy and vaccine development. The timeline for commercialization depends on successful preclinical and clinical studies.
• CBL0137 for Cancer Treatment: CBL0137, a small molecule with a multi-targeted mechanism of action, holds promise for treating various types of cancer. Further research and clinical trials could lead to its development as a novel cancer therapy. The market for small molecule cancer drugs remains significant, despite the rise of biologics. The timeline for commercialization depends on successful preclinical and clinical studies.

What Opportunities Does CBLI Have?

• Government contracts for radiation countermeasures.
• Partnerships with larger pharmaceutical companies.
• Expansion into new therapeutic areas.
• Accelerated approval pathways for orphan drug designations.

What Threats Does CBLI Face?

• Competition from established pharmaceutical companies.
• Clinical trial failures.
• Regulatory setbacks.
• Inability to secure additional funding.

What Are CBLI's Competitive Advantages?

• Proprietary Toll-like receptor technology platform.
• Patent protection for drug candidates.
• Expertise in radiation countermeasure development.
• Established relationships with government agencies (potential).

What Does CBLI Do?

Cleveland BioLabs, Inc., now known as Cytocom, Inc., was founded with the mission of developing innovative approaches to address critical unmet medical needs by harnessing the power of the immune system. Headquartered in Buffalo, New York, the company focuses on researching and developing novel drugs that activate the immune system to combat diseases and mitigate the effects of radiation exposure. Their core technology platform revolves around Toll-like immune receptor activators, which have shown promise in both radiation injury mitigation and immuno-oncology applications. The company's most advanced product candidate is Entolimod, an immuno-stimulatory agent being developed as a radiation countermeasure and an immunotherapy for various oncology indications. Entolimod aims to protect against the harmful effects of radiation exposure and enhance the body's ability to fight cancer. In addition to Entolimod, Cytocom is also developing other products, including CBLB612, Mobilan, and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer. These product candidates represent Cytocom's commitment to advancing innovative therapies for a range of serious medical conditions. Currently, Cytocom employs 18 full-time employees.

What Products and Services Does CBLI Offer?

• Develops drugs that activate the immune system.
• Focuses on Toll-like immune receptor activators.
• Creates radiation countermeasures.
• Develops immunotherapies for oncology.
• Researches and develops CBLB612.
• Researches and develops Mobilan.
• Researches and develops CBL0137.

How Does CBLI Make Money?

• Develops and patents novel drug candidates.
• Conducts preclinical and clinical trials.
• Seeks regulatory approval from agencies like the FDA.
• Out-licenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through government contracts, licensing agreements, and product sales (if approved).

What Industry Does CBLI Operate In?

Cytocom, Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant financial risks. The company's focus on immuno-oncology and radiation countermeasures aligns with growing market trends in personalized medicine and biodefense. The competitive landscape includes established pharmaceutical companies and smaller biotech firms, such as Catalyst Biosciences, Inc. (CATB), Celularity Inc. (CELU), CARGO Therapeutics, Inc. (CRGX), IN8bio, Inc. (INXB) and MACK. Success in this industry requires strong intellectual property, efficient clinical trial execution, and strategic partnerships.

Who Are CBLI's Key Customers?

• Government agencies (for radiation countermeasures).
• Hospitals and oncology centers (for cancer therapies).
• Patients with cancer and radiation exposure risks.
• Pharmaceutical companies (through licensing agreements).

CBLI Financials

CBLI Latest News

CBLI Analyst Consensus

CBLI MoonshotScore

CBLI Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Popular Stocks